BENZIMIDAZOLES USED AS PROTEIN KINASE INHIBITORS Russian patent published in 2011 - IPC C07D403/04 C07D401/14 C07D403/14 A61K31/506 A61K31/4439 A61K31/55 A61K31/551 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula or pharmaceutically acceptable salt thereof; where Q is selected from a group consisting of R¹ denotes H; each R² independently denotes Z^R; each J^Q independently denotes Z^Q, M^Q, (L^Q)-Z^Q or (X^Q)-M^Q; each L^Q and X^Q independently denotes C_1-6alkyl, where each carbon of the alkyl group is independently substituted in up to 2 cases -NR-, -NHR-, -NRC(O)O-; where each X^Q is independently and optionally substituted with 0-2 J^XQ; each Z^R and Z^Q independently denotes H; a C_1-6alkyl group, a 5-7-member saturated or completely unsaturated monocyclic ring, having 0-2 nitrogen atoms; or a 9-member saturated bicyclic ring system having 1 nitrogen atom; where each is Z^Q independently and optionally substituted with 0-3 J^ZQ; M^Q denotes halogen, CN or N(R)₂; each J^LQ, J^XQ and J^ZQ independently denotes V, M, (L^V)-V, (L^M)-M, halogen, C_1-3alkoxy; each R independently denotes H, C_1-6alkyl group; each L^V and L^M independently denotes C_1-6alkyl, interrupted in up to 1 case by -C(O)-; where each V independently denotes H; C_1-6alkyl group, a 5-6-member saturated or completely unsaturated monocyclic ring; where each V is independently or optionally substituted with 0-1 J^V; each J^V denotes NH₂; each M independently denotes halogen, OH, O(C_1-6alkyl), NH₂, provided that when R¹ and R² - H, Q is not The invention also relates to a composition based compounds of formula I, a method of inhibiting activity of Aurora B protein kinase, FLT-3 protein kinase, a method of treating a proliferative disorder, particularly leukaemia or lymphoma and a method of producing compounds of formula I.

EFFECT: novel benzimidazole derivatives are obtained, which can be used as inhibitors of protein kinase Aurora B and FLT-3.

28 cl, 2 tbl, 5 ex